D&A Pharma

www.da-pharma.fr

D&A PHARMA is a Specialty Pharma committed to providing effective and innovative treatments to patients suffering from various addictions (alcohol, opiates, cocaine…). In 2017, the treatment of alcohol and cocaine dependences is still an unmet medical need with more than 100 million patients worldwide suffering from their addictions, developing serious attributable diseases and creating significant burden. D&A PHARMA lead product, ALCOVER, is targeting the treatment of alcohol-dependent patients with a Very High Drinking Risk Level (daily alcohol consumption > 60g for women and > 100g for men). Life expectancy in this population is estimated at only 47 to 61 years, underlying the urgency to treat these patients. ALCOVER has shown to be effective and safe in both the detoxification phase and the long-term maintenance of alcohol abstinence with unprecedented efficacy results in this population. ALCOVER is approved in Italy and Austria and registration is ongoing in 10 other EU countries. Two other pharmacotherapies aiming at treating opiate and cocaine addictions respectively are under development with promising results. Our Culture, Values and Company’s size foster a fast-paced, dynamic, forward-thinking, friendly and team-working environment. Look at our job opportunities and join us!

Read more

Reach decision makers at D&A Pharma

Lusha Magic

Free credit every month!

D&A PHARMA is a Specialty Pharma committed to providing effective and innovative treatments to patients suffering from various addictions (alcohol, opiates, cocaine…). In 2017, the treatment of alcohol and cocaine dependences is still an unmet medical need with more than 100 million patients worldwide suffering from their addictions, developing serious attributable diseases and creating significant burden. D&A PHARMA lead product, ALCOVER, is targeting the treatment of alcohol-dependent patients with a Very High Drinking Risk Level (daily alcohol consumption > 60g for women and > 100g for men). Life expectancy in this population is estimated at only 47 to 61 years, underlying the urgency to treat these patients. ALCOVER has shown to be effective and safe in both the detoxification phase and the long-term maintenance of alcohol abstinence with unprecedented efficacy results in this population. ALCOVER is approved in Italy and Austria and registration is ongoing in 10 other EU countries. Two other pharmacotherapies aiming at treating opiate and cocaine addictions respectively are under development with promising results. Our Culture, Values and Company’s size foster a fast-paced, dynamic, forward-thinking, friendly and team-working environment. Look at our job opportunities and join us!

Read more
icon

Country

icon

City (Headquarters)

Paris

icon

Employees

11-50

icon

Founded

2006

icon

Social

  • icon

Employees statistics

View all employees

Potential Decision Makers

  • Attaché Regulatory Affairs

    Email ****** @****.com
    Phone (***) ****-****
  • Store Keeper

    Email ****** @****.com
    Phone (***) ****-****
  • Responsible for Analytical Development and Quality Control

    Email ****** @****.com
    Phone (***) ****-****

Technologies

(3)

Reach decision makers at D&A Pharma

Free credits every month!

My account

Sign up now to uncover all the contact details